Skip to main content

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

Active, not recruiting · Phase 3 · NCT05908084

Conditions: End Stage Renal Disease (ESRD)

At a glance

Research payments reported, 2025
$712,156
U.S. investigators named
28
Sites paid
28
Planned or actual enrollment
121

About the trial

Sponsor
Humacyte, Inc. (with IQVIA Biotech)
Tested
Acellular Tissue Engineered Vessel (ATEV) (biological), AVF (other)
Dates
Started 2023-09-07; completion 2028-06
Results posted
Not yet

The goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the ATEV and AVF groups over 12 months in patients with end-stage renal disease (ESRD) needing hemodialysis (HD). Participants will be stratified by location of the vascular access (forearm versus upper arm) and by type of AVF creation procedure planned by the surgeon at randomization (1-stage AVF versus 2-stage AVF). The comparator is an upper extremity arterio-venous fistula (AVF) for HD access surgically created per the institution's Standard of Care (SoC).

From ClinicalTrials.gov, last updated 2026-06-26. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Humacyte Global, Inc. reported $712,156 in research payments for this study in 2025 (172 payments).

Products named: Symvess

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.